Approval · Notice of Compliance 16693 · 2015
VYVANSE: Notice of Compliance 16693
Issued March 16, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16693
- Date
- March 16, 2015
- Company
- Shire Pharma Canada UlcToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Central nervous system stimulant
Products in this notice
Medicinal ingredients
- LISDEXAMFETAMINE DIMESYLATE 20 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 30 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 40 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 50 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 60 MG per CAP